ReviewPharmacoEconomics2019

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Sabine E Grimm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.